How injectable opioid agonist treatment (iOAT) care could be improved? service providers and stakeholders’ perspectives

References

• American Society of Addiction Medicine (2019). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 Focused Update. Lippincott Williams & Wilkins. https://doi.org/10.197/ADM.0000000000000633
   Google Scholar
• Archambault, L., Goyer, M. È., Sabetti, J., & Perreault, M. (2022). Implementing injectable opioid agonist treatment: a survey of professionals in the field of opioid use disorders. Drugs: Education, Prevention and Policy, 1-9. https://doi.org/10.1080/09687637.2022.2040007
   Web of Science ®Google Scholar
• Bansback, N., Guh, D., Oviedo-Joekes, E., Brissette, S., Harrison, S., Janmohamed, A., Krausz, M., MacDonald, S., Marsh, D. C., Schechter, M. T., & Anis, A. H. (2018). Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction (Abingdon, England), 113(7), 1264–1273. https://doi.org/10.1111/add.14171
   PubMed Web of Science ®Google Scholar
• BC Coroners Service (2022). Illicit drug toxicity deaths in BC January 1, 2012- September 30, 2022. https://www2.gov.bc.ca/gov/content/life-
   Google Scholar
• Bridges, J. F. P. (2003). Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Applied Health Economics and Health Policy, 2(4):213–224.
   PubMedGoogle Scholar
• British Columbia College of Nurses & Midwives (2022). Scope of practice for registered nurses. www.bccnm.ca
   Google Scholar
• Busse, J. W., Craigie, S., Juurlink, D. N., Buckley, D. N., Li, W., Couban, R. J., Agoritsas, T., Akl, E. A., Carrasco-Labra, A., Cooper, L., Cull, C., da Costa, B. R., Frank, J. W., Grant, G., Iorio, A., Persaud, N., Stern, S., Tugwell, P., Vandvik, P. O., & Guyatt, G. H. (2017). Guideline for opioid therapy and chronic noncancer pain. CMAJ : Canadian Medical Association Journal = Journal de L'Association Medicale Canadienne, 189(18), E659–E666. E666 https://doi.org/10.1503/CMAJ.170363/-/DC1
   PubMed Web of Science ®Google Scholar
• Canadian Research Initiative in Substance Misuse (2019a). National Injectable Opioid Agonist Treatment for Opioid Use Disorder Operational Guidance. https://crism.ca/projects/ioat-guideline/
   Google Scholar
• Canadian Research Initiative in Substance Misuse (2019b). Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline. https://crism.ca/projects/ioat-guideline/
   Google Scholar
• Carter, A., & Hall, W. (2008). Informed consent to opioid agonist maintenance treatment: Recommended ethical guidelines. International Journal of Drug Policy, 19(1), 79–89. https://doi.org/10.1016/j.drugpo.2007.09.007
   PubMed Web of Science ®Google Scholar
• Charland, L. C. (2002). Cynthia’s dilemma: Consenting to heroin prescription. American Journal of Bioethics, 2(2), 37–47. https://doi.org/10.1162/152651602317533686
   PubMedGoogle Scholar
• Charmaz, K. (2008). Grounded Theory as an Emergent Method. (S. N. Hesse-Biber & P. Leavy, Ed.). The Guilford Press.
   Google Scholar
• Cioe, K., Biondi, B. E., Easly, R., Simard, A., Zheng, X., & Springer, S. A. (2020). A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. Journal of Substance Abuse Treatment, 119, 108146. https://doi.org/10.1016/J.JSAT.2020.108146
   PubMed Web of Science ®Google Scholar
• Dassieu, L., Kaboré, J. L., Choinière, M., Arruda, N., & Roy, É. (2019). Chronic pain management among people who use drugs: A health policy challenge in the context of the opioid crisis. The International Journal on Drug Policy, 71, 150–156. https://doi.org/10.1016/J.DRUGPO.2019.03.023
   PubMed Web of Science ®Google Scholar
• Davis, E. L., Kelly, P. J., Deane, F. P., Baker, A. L., Buckingham, M., Degan, T., & Adams, S. (2020). The relationship between patient-centered care and outcomes in specialist drug and alcohol treatment: A systematic literature review. In Substance Abuse, 41(2), 216–231. (Routledge. https://doi.org/10.1080/08897077.2019.1671940
   PubMed Web of Science ®Google Scholar
• Demaret, I., Lemaître, A., & Ansseau, M. (2012). Staff concerns in heroin-assisted treatment centres. Journal of Psychiatric and Mental Health Nursing, 19(6), 563–567. https://doi.org/10.1111/j.1365-2850.2011.01810.x
   PubMed Web of Science ®Google Scholar
• Dobischok, S., Metcalfe, R. K., Matzinger, E. A., Lock, K., Harrison, S., MacDonald, S., Amara, S., Schechter, M. T., Bansback, N., & Oviedo-Joekes, E. (2022). Feasibility of testing client preferences for accessing injectable opioid agonist treatment (iOAT): A pilot study. Patient Preference and Adherence, 16, 3405–3413. https://doi.org/10.2147/PPA.S391532
   PubMed Web of Science ®Google Scholar
• Dobischok, S., Metcalfe, R., Matzinger, E., Palis, H., Marchand, K., Harrison, S., MacDonald, S., Byres, D., Schechter, M., Bansback, N., & Oviedo-Joekes, E. (2023). Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling). International Journal of Drug Policy, 112, 103948. https://doi.org/10.1016/j.drugpo.2022.103948
   PubMed Web of Science ®Google Scholar
• Ekman, I., Swedberg, K., Taft, C., Lindseth, A., Norberg, A., Brink, E., Carlsson, J., Dahlin-Ivanoff, S., Johansson, I.-L., Kjellgren, K., Lidén, E., Öhlén, J., Olsson, L.-E., Rosén, H., Rydmark, M., & Sunnerhagen, K. S. (2011). Person-centered care — Ready for prime time. European Journal of Cardiovascular Nursing, 10(4), 248–251. https://doi.org/10.1016/j.ejcnurse.2011.06.008
   PubMed Web of Science ®Google Scholar
• Entwistle, V. A., Carter, S. M., Cribb, A., & McCaffery, K. (2010). Supporting Patient Autonomy: The importance of clinician-patient relationships. Journal of General Internal Medicine, 2010 25(7), 741–745. https://doi.org/10.1007/S11606-010-1292-2
   Google Scholar
• Eydt, E., Glegg, S., Sutherland, C., Meador, K., Trew, M., Perreault, M., Goyer, M. È., Le Foll, B., Turnbull, J., & Fairbairn, N. (2021). Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. CMAJ Open, 9(1), E115–E124. https://doi.org/10.9778/cmajo.20200021
   PubMedGoogle Scholar
• Ferri, M., Davoli, M., & Perucci, C. A. (2011). Heroin maintenance for chronic heroin‐dependent individuals. The Cochrane Database of Systematic Reviews, 2011(12), CD003410. https://doi.org/10.1002/14651858.CD003410.PUB4
   PubMedGoogle Scholar
• Fischer, B., Jones, W., Tyndall, M., & Kurdyak, P. (2020). Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing-exploratory analyses from Canada. BMC Public Health, 20(1), 143. https://doi.org/10.1186/s12889-020-8205-z
   PubMed Web of Science ®Google Scholar
• Haemmig, R. B., & Tschacher, W. (2001). Effects of high-dose heroin versus morphine in intravenous drug users: a randomised double-blind crossover study. Journal of Psychoactive Drugs, 33(2), 105–110. https://doi.org/10.1080/02791072.2001.10400475
   PubMed Web of Science ®Google Scholar
• Health Canada (2022). Safer supply: Prescribed medications as a safer alternative to toxic illegal drugs. https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/safer-supply.html#a1
   Google Scholar
• Hiltebrand, D., Dey, M., Mayorova, E., Bolliger, H., & Schaub, M. (2016). Traitement avec prescription d’héroïne en Suisse. https://www.addictionsuisse.ch/fileadmin/user_upload/DocUpload/HeGeBe_2015_Jahresbericht_FR.pdf
   Google Scholar
• Hooker, S. A., Sherman, M. D., Lonergan-Cullum, M., Nissly, T., & Levy, R. (2022). What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings. Journal of Substance Abuse Treatment, 141, 108804. https://doi.org/10.1016/j.jsat.2022.108804
   PubMed Web of Science ®Google Scholar
• Jolley, C. J., Bell, J., Rafferty, G. F., Moxham, J., & Strang, J. (2015). Understanding heroin overdose: A study of the acute respiratory depressant effects of injected pharmaceutical heroin. PloS One, 10(10), e0140995. https://doi.org/10.1371/JOURNAL.PONE.0140995
   PubMed Web of Science ®Google Scholar
• Joosten, E. A. G., de Jong, C. A. J., de Weert-Van Oene, G. H., Sensky, T., & van der Staak, C. P. F. (2009). Shared decision-making reduces drug use and psychiatric severity in substance-dependent patients. Psychotherapy and Psychosomatics, 78(4), 245–253. https://doi.org/10.1159/000219524
   PubMed Web of Science ®Google Scholar
• Louie, D. L., Assefa, M. T., & McGovern, M. P. (2019). Attitudes of primary care physicians toward prescribing buprenorphine: A narrative review. BMC Family Practice, 20(1), 157. https://doi.org/10.1186/s12875-019-1047-z
   PubMed Web of Science ®Google Scholar
• MacDonald, S., & Oviedo-Joekes, E. (2022). Chapter 13: Injectable opioid agonist therapy. In P. Selby, L. Rieb, V. Lam, M. Zhang, & J. Bertram (Eds.),Opioid Agonist Therapy: A Prescribers Guide to Treatment (3rd ed.). CAMH.
   Google Scholar
• Marchand, K., Beaumont, S., Westfall, J., MacDonald, S., Harrison, S., Marsh, D. C., Schechter, M. T., & Oviedo-Joekes, E. (2019). Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Substance Abuse Treatment, Prevention, and Policy, 14(1), 37. https://doi.org/10.1186/s13011-019-0227-0
   PubMed Web of Science ®Google Scholar
• Marchand, K., Foreman, J., MacDonald, S., Harrison, S., Schechter, M. T., & Oviedo-Joekes, E. (2020). Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment. Substance Abuse: Treatment, Prevention, and Policy, 15(1), 7. https://doi.org/10.1186/s13011-020-0253-y
   PubMed Web of Science ®Google Scholar
• Marchand, K., Palis, H., Guh, D., Lock, K., MacDonald, S., Brissette, S., Marsh, D. C., Harrison, S., Schechter, M. T., & Oviedo-Joekes, E. (2022). A multi-methods and longitudinal study of patients’ perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use research. Journal of Substance Abuse Treatment, 132, 108512. https://doi.org/10.1016/j.jsat.2021.108512
   PubMed Web of Science ®Google Scholar
• Martins, M. L., Wilthagen, E. A., Oviedo-Joekes, E., Beijnen, J. H., de Grave, N., Uchtenhagen, A., Beck, T., van den Brink, W., & Schinkel, A. H. (2021). The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. Drug and Alcohol Dependence, 227, 108984. https://doi.org/10.1016/J.DRUGALCDEP.2021.108984
   PubMed Web of Science ®Google Scholar
• Merrill, J. O. (2002). Policy progress for physician treatment of opiate addiction. Journal of General Internal Medicine 17, 361–368. https://doi.org/10.1046/j.1525-1497.2002.10628.x
   PubMed Web of Science ®Google Scholar
• Meyer, M., Strasser, J., Köck, P., Walter, M., Vogel, M., & Dürsteler, K. M. (2022). Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic-Is an update of legal restrictions warranted? The International Journal on Drug Policy, 101, 103548. https://doi.org/10.1016/J.DRUGPO.2021.103548
   PubMed Web of Science ®Google Scholar
• Nordt, C., Vogel, M., Dey, M., Moldovanyi, A., Beck, T., Berthel, T., Walter, M., Seifritz, E., Dürsteler, K. M., & Herdener, M. (2019). One size does not fit all—evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction, 114(1), 103–111. https://doi.org/10.1111/add.14442
   PubMed Web of Science ®Google Scholar
• Nowell, L. S., Norris, J. M., White, D. E., & Moules, N. J. (2017). Thematic Analysis: Striving to meet the trustworthiness criteria. International Journal of Qualitative Methods, 16(1), 160940691773384. https://doi.org/10.1177/1609406917733847.
   Web of Science ®Google Scholar
• Office of the Provincial Health Officer (2021). Responding to British Columbia’s Drug Poisoning Crisis. https://www2.gov.bc.ca/gov/content/life-events/death/coroners-service/statistical-reports
   Google Scholar
• Oviedo-Joekes, E., Brissette, S., MacDonald, S., Guh, D., Marchand, K., Jutha, S., Harrison, S., Janmohamed, A., Zhang, D. Z., Anis, A. H., Krausz, M., Marsh, D. C., & Schechter, M. T. (2017). Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder. Drug and Alcohol Dependence, 176, 55–62. https://doi.org/10.1016/j.drugalcdep.2017.02.021
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes, E., MacDonald, S., Boissonneault, C., & Harper, K. (2021). Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Substance Abuse: Treatment, Prevention, and Policy, 16(1), 22. https://doi.org/10.1186/s13011-021-00358-x
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes, E., Palis, H., Guh, D., Marchand, K., Brissette, S., Harrison, S., MacDonald, S., Lock, K., Anis, A. H., Marsh, D. C., & Schechter, M. T. (2019). Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods. Journal of Substance Abuse Treatment, 101, 50–54. https://doi.org/10.1016/j.jsat.2019.03.012
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes, E., Palis, H., Guh, D., Marsh, D. C., MacDonald, S., Harrison, S., Brissette, S., Anis, A. H., & Schechter, M. T. (2019). Adverse events during treatment induction with injectable diacetylmorphine and hydromorphone for opioid use disorder. Journal of Addiction Medicine, 13(5), 354–361. https://doi.org/10.1097/ADM.0000000000000505
   PubMed Web of Science ®Google Scholar
• Panagiotoglou, D., McCracken, R., Lavergne, M. R., Strumpf, E. C., Gomes, T., Fischer, B., Brackett, A., Johnson, C., & Kendall, P. (2020). Evaluating the intended and unintended consequences of opioid-prescribing interventions on primary care in British Columbia, Canada: Protocol for a retrospective population-based cohort study. BMJ Open, 10(11), e038724. https://doi.org/10.1136/bmjopen-2020-038724
   PubMed Web of Science ®Google Scholar
• Park, S. E., Mosley, J. E., Grogan, C. M., Pollack, H. A., Humphreys, K., D'Aunno, T., & Friedmann, P. D. (2020). Patient-centered care’s relationship with substance use disorder treatment utilization. Journal of Substance Abuse Treatment, 118, 108125. https://doi.org/10.1016/j.jsat.2020.108125
   PubMed Web of Science ®Google Scholar
• Pharmascience Inc. (2022). Product monograph including patient medication information Diacetylmorphine Hydrochloride (diamorphine hydrochloride for injection). https://pdf.hres.ca/dpd_pm/00064756.pdf
   Google Scholar
• Piske, M., Zhou, H., Min, J. E., Hongdilokkul, N., Pearce, L. A., Homayra, F., Socias, M. E., McGowan, G., & Nosyk, B. (2020). The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. Addiction, 115(8), 1482–1493. https://doi.org/10.1111/add.14947
   PubMed Web of Science ®Google Scholar
• River Stone Recovery Centre (2021). River Stone Recovery Centre: Our Services. https://www.riverstone.recoverynb.ca/services
   Google Scholar
• Room, R. (2002). Heroin maintenance and attraction to treatment. European Journal of Public Health, 12(3), 234–235. https://doi.org/10.1093/eurpub/12.3.234
   PubMed Web of Science ®Google Scholar
• Roux, P., Rojas Castro, D., Ndiaye, K., Briand Madrid, L., Laporte, V., Mora, M., Maradan, G., Morel, S., Spire, B., & Carrieri, P. (2017). Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: Results from a community-based survey in France. Substance Abuse: Treatment, Prevention, and Policy, 12(1), 1–11. https://doi.org/10.1186/S13011-017-0131-4
   PubMedGoogle Scholar
• Sanders, J. J., Roose, R. J., Lubrano, M. C., & Lucan, S. C. (2013). Meaning and methadone: Patient perceptions of methadone dose and a model to promote adherence to maintenance treatment. Journal of Addiction Medicine, 7(5), 307–313. https://doi.org/10.1097/ADM.0b013e318297021e
   PubMed Web of Science ®Google Scholar
• Sandoz Canada Inc (2021). HYDROmorphone HP 10 (10 mg/mL Sterile Solution for Injection) https://produits-sante.canada.ca/dpd-bdpp/info.do?lang=en&code=68787
   Google Scholar
• Simon, A. (2020). Ethical issues concerning patient autonomy in clinical practice. In M. Kühler & V. L. Mitrović (Eds.), Theories of the Self and autonomy in medical ethics. 123–135. Switzerland: Springer International Publishing. https://doi.org/10.1007/978-3-030-56703-3_8
   Google Scholar
• Socías, M. E., Dong, H., Wood, E., Brar, R., Richardson, L., Hayashi, K., Kerr, T., & Milloy, M.-J. (2020). Trajectories of retention in opioid agonist therapy in a Canadian setting. International Journal of Drug Policy, 77, 102696. https://doi.org/10.1016/j.drugpo.2020.102696
   PubMed Web of Science ®Google Scholar
• Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 357, j1550. https://doi.org/10.1136/BMJ.J1550
   PubMed Web of Science ®Google Scholar
• Starks, H., & Trinidad, S. B. (2007). Choose your method: A comparison of phenomenology, discourse analysis, and grounded theory. Qualitative Health Research, 17(10), 1372–1380. https://doi.org/10.1177/1049732307307031
   PubMed Web of Science ®Google Scholar
• Strang, J., Groshkova, T., Uchtenhagen, A., van den Brink, W., Haasen, C., Schechter, M. T., Lintzeris, N., Bell, J., Pirona, A., Oviedo-Joekes, E., Simon, R., & Metrebian, N. (2015). Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. The British Journal of Psychiatry, 207(1), 5–14. https://doi.org/10.1192/bjp.bp.114.149195
   PubMed Web of Science ®Google Scholar
• Strang, L., & Taylor, J. (2018). Heroin-Assisted Treatment and Supervised Drug Consumption Sites: Experience from Four Countries. www.rand.org/giving/contribute
   Google Scholar
• Suhonen, R., & Charalambous, A. (2018). Individualized Care: The concept of individualised care. In R. Suhonen, M.Stolt & E. Papastavrou(Eds.), Individualized Care: Theory, Measurement, Research and Practice. Springer International Publishing. https://doi.org/10.1007/978-3-319-89899-5_4
   Google Scholar
• Svirsky, L. (2021). Opioid treatment agreements and patient accountability. The Hastings Center Report, 51(4), 46–49. https://doi.org/10.1002/hast.1273
   PubMed Web of Science ®Google Scholar
• The Federal Council of the Swiss Government (2020). Coronavirus: The Federal Council adapts the criteria for the delivery of medical heroin. Berne. https://www.admin.ch/gov/fr/accueil/documentation/communiques.msg-id-80511.html
   Google Scholar
• Thorne, S. (2008). Interpretive Description (1st ed.). Left Coast Press. https://doi.org/10.4324/9781315426259
   Google Scholar
• Thorne, S. (2016). Interpretive description: Qualitative research for applied practice, Second edition. Interpretive Description: Qualitative Research for Applied Practice., Second Edition, 1–336. New York: Routledge.https://doi.org/10.4324/9781315545196
   Google Scholar
• Thorne, S., Kirkham, S. R., & Flynn-Magee, K. O. (2004). The analytic challenge in interpretive description. 3(1), 1–11. https://doi.org/10.1177/160940690400300101
   Google Scholar
• Vogel, M., Dürsteler, K. M., Walter, M., Herdener, M., & Nordt, C. (2017). Rethinking retention in treatment of opioid dependence—The eye of the beholder. International Journal of Drug Policy. 39, 109–113. https://doi.org/10.1016/j.drugpo.2016.09.003
   Google Scholar
• World Health Organization (2009). Methadone maintenance treatment - Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings. https://www.ncbi.nlm.nih.gov/books/NBK310658/
   Google Scholar
• Wright, N., D'Agnone, O., Krajci, P., Littlewood, R., Alho, H., Reimer, J., Roncero, C., Somaini, L., & Maremmani, I. (2016). Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience. Journal of Public Health (Oxford, England), 38(3), e368–e374. https://doi.org/10.1093/PUBMED/FDV150
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Friedmann, P. D., & Gerstein, D. R. (2003). Does retention matter? Treatment duration and improvement in drug use. Addiction, 98(5), 673–684. https://doi.org/10.1046/J.1360-0443.2003.00354.X
   PubMed Web of Science ®Google Scholar